Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: CO who wrote (1596)	9/9/1998 2:27:00 PM
From: Archie Goodwin	Respond to of 4650

News........... (COMTEX) B: Biomoda, Inc. Receives Offer to Take Company Public; Move B: Biomoda, Inc. Receives Offer to Take Company Public; Move Would Have Positive Impact on Advanced Optics Electronics ALBUQUERQUE, N.M. (Sept. 9) BUSINESS WIRE -Sept. 9, 1998--Advanced Optics Electronics, Inc. (OTC BB: ADOT) today announced that Biomoda, Inc. has notified Advanced Optics that Biomoda has received a preliminary offer from an investment banking firm to take Biomoda, Inc. public. The Company will release specifics of this proposed public offering of Biomoda shares as negotiations progress. Advanced Optics Electronics owns approximately 22% of Biomoda, Inc., with an option to increase its holdings to 27%. Biomoda, Inc. owns a patented lung cancer test capable of detecting lung cancer up to six years earlier than any other available test. A final double-blind study of the effectiveness of Biomoda's revolutionary non-invasive test is currently being conducted by LungCheck(R), Inc. of Scottsdale, Ariz., with results expected to be completed by the end of September. These results will be sent for confirmation to a prestigious institution on the East coast, with further confirmation expected by the first week in October. Verified results will be submitted to various medical journals for publication as well as to the national media. Biomoda's technology also encompasses the treatment of lung cancer. Biomoda's prominent research team has included world-leading cytopathologists, Dr. Geno Saccomanno of St. Mary's Hospital and Medical Center, Dr. Jim Mulshine of the National Cancer Institute and the late Dr. John Frost of Johns Hopkins University. Also currently involved in Biomoda's research is Dr. L. Edward Ellinwood, a nationally recognized pharmacologist from St. Mary's Hospital and Los Alamos National Laboratories. Biomoda believes this technology is a leading hope for a cure for lung cancer. FDA approval will not be necessary for the patented non-invasive lung cancer test, but will be required for the patented treatment process. Brian $^)